Please assess the completion status of the following clinical trial:

Trial Title: CMV Antiviral Prevention Strategies in D+R-Liver Transplants (CAPSIL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be \> / = 18 years of age.~2. Have negative Cytomegalovirus (CMV) serology (confirmed within 6 months of transplant) and receive a liver from a donor with positive CMV serology (R-/D+).~3. Have received their first orthotopic liver transplant (the transplanted liver may be deceased donor or live donor graft) within 10 days prior.~4. Have absolute neutrophil count \> 1000/µL at randomization.~5. - If female, and not postmenopausal or surgically sterile, must have negative pregnancy test (serum or urine) within 48 hours prior to randomization and must also agree to use medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence for 100 days after randomization and 3 months after valganciclovir cessation.~   -- If male, and has not had a vasectomy, he must agree to practice barrier method of contraception for 100 days after randomization and 3 months after valganciclovir cessation.~6. Subject or legally authorized representative has provided written informed consent.~Exclusion Criteria:~1. Currently enrolled in any interventional trial of an investigational therapeutic agent unless co-enrollment has been approved by study Principal Investigators (PIs) and the DMID prior to enrollment.~2. Have hypersensitivity to acyclovir, ganciclovir or valganciclovir.~3. Be breast-feeding mother.~4. Have known Human immunodeficiency virus (HIV) infection (based on testing performed during the transplant evaluation process).~5. Be undergoing multi organ transplant or have undergone prior organ transplant.~6. Have expected life expectancy of less than 72 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Preemptive Therapy (Type: EXPERIMENTAL): 900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
- Prophylaxis (Type: ACTIVE_COMPARATOR): 900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88

Based on this trial design, predict the completion outcome and termination type (if applicable).